GSK plc

GSK plc is a British multinational pharmaceutical and biotechnology company headquartered in London, England. The company's core mission is to unite science, technology, and talent to get ahead of disease, aiming to discover, develop, and deliver medicines and vaccines that create value for patients and shareholders. GSK strives to positively impact the health of 2.5 billion people by the end of the decade.

GSK's primary focus areas include vaccines, specialty medicines, and general medicines. Its product portfolio addresses a wide range of therapeutic areas such as infectious diseases, HIV, respiratory illnesses, immunology, inflammation, and oncology. Key products include vaccines like Shingrix for shingles and Arexvy for respiratory syncytial virus (RSV), as well as HIV treatments through its majority-owned ViiV Healthcare.

In recent years, GSK has undergone significant strategic shifts, notably spinning off its consumer healthcare business into Haleon in 2022 to sharpen its focus on biopharmaceuticals. The company has also expanded its pipeline through targeted acquisitions, including Sierra Oncology, Affinivax, Bellus Health Inc., and Aiolos Bio, enhancing its capabilities in oncology, vaccines, respiratory, and immunology. Emma Walmsley is the current CEO, with Luke Miels slated to take over on January 1, 2026.